The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Malaysia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.
In 2013, Malaysia’s population stood at 29.9 million. The past five years have seen steady population growth, which is expected to continue in the future due to a high birth rate, low mortality rate and increased life expectancy. Government initiatives such as Entry Point Projects (EPPs), specifically EPP3, and National Key Economic Areas (NKEAs) to increase investment in the pharmaceutical industry have so far have been successful. The country’s pharmaceutical market was estimated at $1.2 billion in 2008 and is projected to reach approximately $3.7 billion by 2020 at a CAGR of 9.5%. The medical device market was worth approximately $585m in 2010, but is growing and currently constitutes approximately 25% of the healthcare expenditure.
Complete report is available @ http://www.rnrmarketresearch.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-malaysia-market-report.html .
